Khushboo Patel
Family · Orange City, FLNPI 1043852783
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 261 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,804, 2.3 times the $798 reported in 2021. Among family clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 261 payments — averaging $21.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$656
- Actelion Pharmaceuticals US, Inc.$565
- Boehringer Ingelheim$348
- Insmed, Inc.$320
- Mallinckrodt Hospital Products Inc.$297
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,32596%
- Education$1994%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 55 | $1,123 |
| GSK | 40 | $656 |
| Actelion Pharmaceuticals US, Inc. | 16 | $565 |
| Boehringer Ingelheim | 17 | $348 |
| Insmed, Inc. | 13 | $320 |
| Mallinckrodt Hospital Products Inc. | 13 | $297 |
| Inogen, Inc. | 21 | $283 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $270 |
| Merck | 7 | $162 |
| Regeneron Healthcare Solutions, Inc. | 5 | $149 |
| United Therapeutics Corporation | 3 | $148 |
| Verona Pharma, Inc. | 6 | $139 |
| Electromed, Inc. | 11 | $122 |
| Pulmonx Corporation | 6 | $118 |
| Harmony Biosciences LLC | 4 | $110 |
| Grifols USA, LLC | 4 | $88 |
| Baxter Healthcare | 4 | $81 |
| Mylan Specialty L.p. | 3 | $70 |
| Cvrx, Inc. | 2 | $68 |
| Amgen | 3 | $65 |
| Jazz Pharmaceuticals Inc. | 3 | $49 |
| Teva Pharmaceuticals USA, Inc. | 3 | $49 |
| Vifor Pharma, Inc. | 2 | $46 |
| Abbott | 2 | $37 |
| Advanced Respiratory, Inc | 2 | $33 |
| Sanofi | 1 | $30 |
| Novartis | 1 | $27 |
| Boston Scientific | 1 | $21 |
| Philips North America LLC | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$100
How this compares
$5,524 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 425 | $350,183 |
| Breo ElliptaFluticasone/Vilanterol | 189 | $92,833 |
| Spiriva RespimatTiotropium Bromide | 32 | $25,318 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $20,789 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 35 | $18,336 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 262 | $6,412 |
| Incruse ElliptaUmeclidinium Bromide | 18 | $6,208 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $4,768 |
| Arnuity ElliptaFluticasone Furoate | 18 | $3,553 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $1,897 |
| Azithromycin | 84 | $959 |
| Prednisone | 215 | $847 |
| Ventolin HfaAlbuterol Sulfate | 11 | $731 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 13 | $676 |
| Fluticasone Propionate | 11 | $491 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $656 | $471,112685 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,123 | $25,55642 claims |
| Boehringer IngelheimSpiriva Respimat | $348 | $25,31832 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in Orange City
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
- Ronda CrewsJax Bch$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.